Phreesia Inc

Phreesia Inc(PHR)股票分析

$11.840

-0.359 (-3.03%)收盘时

Loading chart…
High
12.220
Open
11.990
VWAP
11.94
Vol
506.25K
Mkt Cap
1.21B
Low
11.770
Amount
6.05M
EV/EBITDA, TTM
12.35

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.

AI analysis of Phreesia Inc (PHR)

hold

Phreesia Inc is currently priced at $12.15, which is very close to the analyst price target of $12 from Piper Sandler. The stock has shown a recent upward trend with a 5-day change of +0.25% and a significant 20-day change of +13.23%. However, insider selling has increased by 190.73%, indicating potential concerns about the company's future performance. The RSI is at 61.945, suggesting it is nearing overbought territory, which could limit short-term upside. Given these factors, it may be prudent to hold rather than buy at this time, as the stock is near its target price and insider selling raises red flags.

估值指标

The current forward P/E ratio for Phreesia Inc (PHR) is 15.82, compared to its 5-year average forward P/E of 2.60.

Forward P/E

Fair
5Y Average P/E
2.60
Current P/E
15.82
高估
191.99
低估
-186.79

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-23.75
Current EV/EBITDA
12.35
高估
96.29
低估
-143.78

Forward P/S

Fair
5Y Average P/S
3.99
Current P/S
1.40
高估
6.93
低估
1.05

Alphio AI Price Scenarios for PHR

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PHR

$23.17

情景价格

B

Base

Base · 50%PHR

$22.64

情景价格

B

Bear

Bear · 25%PHR

$21.67

情景价格

Whales holding PHR

R

Rock Springs Capital Management LP

+ HoldingPHR

+19.26%

3M Return

G

Granahan Investment Management, LLC

+ HoldingPHR

+11.84%

3M Return

D

Deerfield Management Company, L.P.

+ HoldingPHR

-4.62%

3M Return

事件时间线

2026-06-11 (ET)

14:30:00

Jeff Bezos' New AI Venture Prometheus Raises $12B, Valuation Reaches $41B

2026-05-27 (ET)

19:50:00

WTI Crude Oil Falls Below $90, Energy Sector Worst Performer

16:30:00

Phreesia Up 12% to $10.21 After Q1 Results, Affirms Guidance

16:30:00

Phreesia Maintains Fiscal 2027 Revenue Outlook at $510M to $520M

16:10:00

Phreesia Q1 Revenue $130.9M, Beats Expectations

资讯

PHR FAQ — answered by Alphio AI

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

Phreesia Inc is currently priced at $12.15, which is very close to the analyst price target of $12 from Piper Sandler. The stock has shown a recent upward trend with a 5-day change of +0.25% and a significant 20-day change of +13.23%. However, insider selling has increased by 190.73%, indicating potential concerns about the company's future performance. The RSI is at 61.945, suggesting it is nearing overbought territory, which could limit short-term upside. Given these factors, it may be prudent to hold rather than buy at this time, as the stock is near its target price and insider selling raises red flags.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始